Results 121 to 130 of about 16,754,236 (393)

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha   +6 more
wiley   +1 more source

Technology mapping: Leukemia Treatment

open access: yesRevista CENIC Ciencias Químicas, 2015
The increase in the incidence of various cancers has been one of the biggest challenges in the global public health for decades. Leukemia is a type of cancer that only in 2008 has affected 351,000 people of the world population.
Luciene Ferreira Gaspar Amaral   +2 more
doaj  

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini   +11 more
wiley   +1 more source

Las obras huérfanas en el Derecho europeo

open access: yesRevista Iberoamericana de la Propiedad Intelectual, 2016
En el Derecho Comunitario, las obras huérfanas están reguladas mediante la Directiva 2012/28/UE, de 25 de octubre, sobre ciertos usos autorizados de las obras huérfanas (en adelante, DOH).
Sebastián López Maza
doaj  

Property [PDF]

open access: yes, 2013
Oldenburg, E. W.
core   +2 more sources

PROPERTY VALUES

open access: yesThe Proceedings of the Festschrift in Honor of Bruce H J Mckellar and Girish C Joshi, 2007
By ascribing a complex anticommuting variable ζ to each basic property of a field it is possible to describe all the fundamental particles as combinations of only five ζ and understand the occurrence of particle generations. An extension of space-time x to include property then specifies the 'where, when and what' of an event and allows for a ...
openaire   +2 more sources

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

open access: yesMolecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke   +12 more
wiley   +1 more source

La Superintendencia de Industria y Comercio en facultades jurisdiccionales respecto de infracción de derechos de propiedad industrial. Precedentes de la oralidad

open access: yesRevista Iberoamericana de la Propiedad Intelectual, 2015
En virtud del artículo 24 del Código General del Proceso (Ley 1564 de 12 de julio de 2015) a la Superintendencia de Industria y Comercio –de ahora en adelante SIC- le fueron otorgadas facultades o competencias jurisdiccionales para resolver infracciones
Juan Felipe Acosta Sánchez
doaj  

Integrative analysis of circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients: a comprehensive approach

open access: yesMolecular Oncology, EarlyView.
This study simultaneously investigated circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients. The elevated expression of JUNB and CXCR4 in CTCs was a poor prognostic factor for SCLC patients, whereas exosomal overexpression of these biomarkers revealed a high discrimination ability of patients from healthy individuals,
Dimitrios Papakonstantinou   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy